Drugs / AQ001S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04933383 | Jul 2021 → Dec 2022 | asthma | Aquilon Pharmaceuticals S.A. | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AQ001S | “AQ001S 0.125 mg/ml is a budesonide inhalation solution administered by nebulization once daily.” NCT04933383 ↗ |
| Known as | AQ001S 0.125 mg/ml | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04933383 ↗ |
| Route | Other | “administered by nebulization once daily” NCT04933383 ↗ |